121 related articles for article (PubMed ID: 36729405)
1. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract][Full Text] [Related]
2. WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6.
Ji J; Liu W; Xu Y; Xu Z; Lv M; Feng J; Lv J; He X; Zhang Z; Xie M; Jing A; Wang X; Ma J; Liu B
Front Pharmacol; 2022; 13():1072194. PubMed ID: 36744210
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract][Full Text] [Related]
5. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
6. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract][Full Text] [Related]
7. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
8. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
9. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
10. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
12. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
13. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
14. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Chen D; Sun X; Zhang X; Cao J
Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
[TBL] [Abstract][Full Text] [Related]
16. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
17. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
20.
Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
